logo-loader
Futura Medical PLC

Futura Medical PLC - Block Listing Six Monthly Return

RNS Number : 1043W
Futura Medical PLC
06 December 2019
 

Block Listing Six Monthly Return

6 December 2019

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

Date: 6 December 2019

Name of applicant:

Futura Medical Plc

Name of scheme:

Unapproved Share Option Scheme

Unapproved Share Incentive Scheme

EMI Share Option Scheme

Period of return:

From:

1 June 2019

To:

30 November 2019

Balance of unallotted securities under scheme(s) from previous return:

6,225,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

n/a

Less:  Number of securities issued/allotted under scheme(s) during period:

n/a

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

6,225,000

Number and class of securities originally admitted and the date of admission

USOS Total: 3,882,912

814,424 25 May 2011

1,202,280             8 October 2013

1,466,208             25 May 2017

400,000                30 May 2018

 

USIS Total: 425,000

425,000                30 November 2018

 

EMI Total: 7,012,088

1,520,576             25 May 2011

1,467,720             8 October 2013

1,893,792             25 May 2017

790,000                 30 May 2018

1,340,000             30 November 2018

         

 

 

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
 

Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension.  FM57 is progressing on track, with headline data expected by the end of 2019.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRTFBFTMBMMBRL
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Futura Medical marks pivotal year with first meaningful revenue from Eroxon...

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company as it rolled out its innovative sexual health product, Eroxon, designed to treat erectile dysfunction. The over-the-counter availability of Eroxon distinguishes...

on 02/07/2024

3 min read